1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies

Baron Funds Comments on BioScrip Inc.

February 26, 2014 | About:

BioScrip, Inc. (NASDAQ:BIOS), an operator of infusion therapy pharmacies, fell 16.5% for the Fund in the quarter. While the company continues to execute its strategy of consolidating the infusion services industry, it stumbled after a non-core legacy business performed worse than expected. While the miscue is not dire for the company, it hurt management's credibility after it had to reset guidance. We continue to believe there is substantial value and growth in the core infusion business, and that this has been validated by CVS's purchase in December of the number two player in the space, Coram, for a very high multiple of cash flow.

From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 letter to shareholders.


Rating: 3.5/5 (2 votes)

Comments

Please leave your comment:


GuruFocus has detected 6 Warning Signs with BioScrip Inc $BIOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

User Generated Screeners


kw1123Non_S&P Buy
kw1123S&P Buy
dpostelBook Appreciation
nmccutcheonMID CAP
DANGORDON*
DANGORDONBOOK VAL GROWTH RATE 2-12-17
nmccutcheonMid-cap value
Marty Fletcher10% ROE ROC 12 PE
milesahead04smallCap AllAround2
milesahead04smallCap AllAround
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK